readthroughSign in
Oct 29, 2026Trial update

Takeda registers observational RETRACE study on real-world narcolepsy type 1 treatment patterns

Takeda listed a new non-interventional study tracking how adults with narcolepsy type 1 in Europe and Canada are diagnosed, treated, and managed over time.

Takeda's single registry update this week covers a new observational study in narcolepsy type 1 (NT1).

  • "Real-World Treatment Patterns in Narcolepsy Type 1" (NCT07903220, sponsor ID TAK-861-3009, acronym RETRACE) is an observational study sponsored by Takeda with status listed as not yet recruiting.1 The study is designed to better understand how people with NT1 are treated in real-world practice, including the reasons behind treatment changes and how different treatment approaches affect symptoms, cataplexy, and quality of life over time.1 It includes a retrospective cohort and a prospective cohort, the latter enrolling participants with NT1 who initiate treatment with pitolisant or sodium oxybate, either alone or combined with other narcolepsy treatments, starting on the day of enrollment or within 28 days afterward.1 Enrollment is estimated at 400 participants1, with primary completion estimated for 2027-09-30.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.